Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 535 participants.
Also called NCT02121717
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 535 participants
- Sponsor
- Registry
-
NCT02121717
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02121717. Randomized; double masking; primary purpose treatment. Start 2014-06 (registry gives no type); primary completion 2017-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients
- Acronym
- CMAP
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Chiglitazar
- Intervention (Drug)
- Placebo
- Lead sponsor
- Chipscreen Biosciences, Ltd.
Record details
- Record id
cardio:ct-nct02121717- Content hash
41d6e525cd82685502d1f26683164b19c5bd026ebf74757baafe2a20511fe98c